Skip to main content

Table 1 Response rates of an IBDV therapeutic vaccine on acute HBV and HCV infections

From: Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs

Response HBV HCV
  IBDV control IBDV control
Progression into CAHb 0/20 (0%) 3/23*a (13%) 2/22 (9%) 5/19* (26%)
Relapses 1/20 (5%) 2/23 (9%) 7/22 (32%) 15/19*** (79%)
Late remissionc 0/20 (0%) 4/23** (17%) 3/22 (14%) 8/19** (42%)
Fast remissiond 10/20 (50%) 6/23 (26%) 11/22 (50%) 4/19 (21%)
Duratione (weeks ± SD) 5.9 ± 3.0 7.5 ± 3.7 5.3 ± 4.4 8.9 ± 7.4
  1. aSignificance (p value, chi-square, Yates’ correction): *p < 0.05; **p < 0.02; ***p < 0.01;
  2. bChronic active hepatitis
  3. cRemission over 6 months
  4. dRemission within 1 month
  5. eDuration of the first icteric phase